Exosome Biogenesis in Neurodegeneration
Overview
Exosome Biogenesis in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
Exosomes are small extracellular vesicles (30-150 nm) that mediate intercellular communication by transferring proteins, lipids, RNA, and DNA between cells. In the nervous system, exosomes play crucial roles in synaptic plasticity, immune regulation, and the spreading of pathological proteins in neurodegenerative diseases [@thry2002]. These nanoscale vesicles are increasingly recognized as critical players in the pathogenesis of Alzheimer's disease, Parkinson's disease, and related disorders.
Exosome biogenesis represents a promising therapeutic target for neurodegenerative disorders due to its role in:
- Pathological protein propagation (Aβ, tau, alpha-synuclein)
- Immune system modulation and neuroinflammation
- Biomarker discovery through CSF and blood exosomes
- Drug delivery vehicles for CNS therapeutics
Biogenesis Pathway
Endosomal Sorting Complex Required for Transport (ESCRT)
The ESCRT machinery drives multivesicular body (MVB) formation, the cellular process by which intralumenal vesicles are generated within endosomes [@hanson2012]:
Mermaid diagram (expand to render)
| ESCRT Component | Function | Neurodegeneration Relevance |
|-----------------|----------|----------------------------|
| ESCRT-0 (HRS, STAM1/2) | Cargo recognition | Altered in AD |
| ESCRT-I (TSG101, VPS37) | Membrane recruitment | Reduced in PD |
| ESCRT-II (VPS36, VPS22) | Bud formation | Dysregulated in tauopathies |
| ESCRT-III (CHMP2, CHMP4) | Vesicle scission | Impaired in ALS |
| VPS4 (VPS4A/B) | Complex recycling | Required for function |
ESCRT-Independent Pathways
While ESCRT-dependent exosome formation is well-characterized, multiple ESCRT-independent mechanisms contribute to exosome biogenesis [@trajkovic2008]:
Ceramide-dependent pathway:
- Neutral sphingomyelinase (nSMase) generates ceramide from sphingomyelin
- Ceramide promotes spontaneous inward budding of exosome membranes
- Inhibited by GW4869, a commonly used nSMase inhibitor
- Critical for exosome release in neurons
Syndecan-dependent pathway:
- Syndecans (1-4) are heparan sulfate proteoglycans
- Interact with syntenin through their cytoplasmic domains
- ALIX bridges syntenin to ESCRT-III
- Regulates exosome release in response to cellular stress
CD63-rich microdomains:
- Tetraspanins (CD9, CD63, CD81, CD82) organize into microdomains
- Concentrate specific cargo proteins
- CD63 particularly enriched in neuron-derived exosomes
Molecular Regulation of Exosome Release
Mermaid diagram (expand to render)
Exosome Content and Composition
Protein Cargo
Exosomes contain a characteristic set of proteins that reflect their cellular origin [@kalani2014]:
| Category | Examples | Significance |
|----------|----------|--------------|
| Tetraspanins | CD9, CD63, CD81, CD82 | Surface markers |
| ESCRT components | Alix, TSG101, VPS4 | Biogenesis machinery |
| Heat shock proteins | Hsp70, Hsp90 | Stress response |
| MHC molecules | HLA-DR, HLA-A | Immune function |
| Metabolic enzymes | GAPDH, LDH | Metabolic state |
| Neuro-specific | Synaptophysin, N-Cadherin | Neuronal origin |
Nucleic Acid Cargo
Exosomes package various RNA species that can regulate gene expression in recipient cells [@valadi2007]:
- mRNA: Full-length transcripts for protein translation
- miRNA: Regulatory small RNAs affecting post-transcriptional regulation
- lncRNA: Long non-coding RNAs including MALAT1, NEAT1
- circRNA: Circular RNAs with regulatory functions
- mtDNA: Mitochondrial DNA fragments
Lipid Composition
Exosomes are enriched in specific lipids that affect their function:
- Cholesterol and sphingomyelin (membrane rigidity)
- Ceramide (raft domains, signaling)
- Phosphatidylserine (cell internalization)
- Phosphoglycerides (membrane structure)
Role in Neurodegeneration
Alzheimer's Disease
Exosomes in AD serve dual roles—both propagating pathology and potentially clearing toxic proteins [@asai2015]:
Pathological spreading:
- Aβ oligomers are packaged into exosomes and transferred between neurons
- Exosomal Aβ is more aggregation-prone than free Aβ
- Tau propagates via exosomal transport between synaptically connected neurons
- Exosome-associated tau is more efficiently taken up by naive neurons
Protective mechanisms:
- Exosomes can sequester Aβ and reduce extracellular toxicity
- Glial exosomes promote Aβ clearance through apoE-mediated pathways
- Exosomal neprilysin degrades Aβ peptides
Mermaid diagram (expand to render)
Parkinson's Disease
Exosomes play a central role in alpha-synuclein propagation in PD [@stuendl2016]:
- Alpha-synuclein prion-like spread via exosomes
- Exosomal alpha-synuclein is more potent than free protein
- Neuron-glia exosome transfer propagates pathology
- GBA mutations affect exosome release and composition
Key mechanisms:
- RAB27B regulates exosome release in dopaminergic neurons [@guo2020]
- LRRK2 mutations alter exosome biogenesis [@matsumoto2017]
- PINK1 and PARKIN affect exosome cargo
Amyotrophic Lateral Sclerosis (ALS)
Exosome-mediated pathology spread in ALS [@fischer2016]:
- TDP-43 protein aggregates transfer via exosomes
- C9orf72 repeat expansions produce toxic RNA species in exosomes
- SOD1 mutant protein propagates through exosomal pathways
- Astrocyte exosomes contribute to motor neuron toxicity
Huntington's Disease
- Mutant huntingtin protein packages into exosomes
- Exosomal miRNA cargo reflects disease state
- Exosome-mediated spread of polyglutamine aggregates
Therapeutic Applications
Exosome-Based Drug Delivery
Engineered exosomes offer advantages for CNS drug delivery [@alvarezerviti2011]:
Advantages:
- Blood-brain barrier penetration capability
- Reduced immunogenicity compared to synthetic nanoparticles
- Ability to target specific cell types through surface engineering
- Protection of cargo from degradation
Engineering approaches:
- Surface ligand display for targeting (e.g., rabies glycoprotein peptide)
- Cargo loading via electroporation or sonication
- Exosome production from engineered cell lines
Therapeutic Exosome Modification
| Modification | Purpose | Example |
|-------------|---------|---------|
| Surface targeting | Cell-specific delivery | RVG peptide for neurons |
| Anti-inflammatory | Reduce immune response | CD47 display |
| Therapeutic cargo | Treat disease | siRNA, proteins |
| Enhanced release | Increase efficacy | RAB27A overexpression |
Clinical Trials
Several clinical trials are evaluating exosome-based therapies:
- Mesenchymal stem cell (MSC)-derived exosomes for AD
- Exosome-based vaccine approaches
- Engineered exosomes for PD
Research Methods
Exosome Isolation Techniques
| Method | Principle | Pros | Cons |
|--------|-----------|------|------|
| Ultracentrifugation | Size/density | Gold standard | Time-consuming |
| Size-exclusion chromatography | Size | Gentle, pure | Lower yield |
| Immunoaffinity | Surface markers | Highly specific | Limited capacity |
| Precipitation | Polymers | High yield | Contaminants |
Characterization Methods
- NTA (Nanoparticle Tracking Analysis): Size distribution
- Western blot: Protein markers (CD63, CD9, Alix)
- EM (Electron Microscopy): Morphology
- Flow cytometry: Surface markers
Biomarker Discovery
Neuronal exosomes in cerebrospinal fluid and blood provide disease-specific signatures [@fiandaca2015]:
- AD: Elevated Aβ42, p-tau181, p-tau217
- PD: Alpha-synuclein, LRRK2, GBA
- ALS: TDP-43, SOD1, C9orf72
Cross-Linking to Neurodegeneration Mechanisms
Autophagy-Exosome Relationship
The autophagy and exosome pathways intersect at multiple points [@baixauli2014]:
- Common ESCRT machinery components
- Autophagy proteins regulate exosome release
- MVB fate determined by cellular stress
- Lysosomal dysfunction affects both pathways
Mitochondrial Dysfunction
Exosomes carry mitochondrial components:
- Mitochondrial DNA detected in neuron-derived exosomes
- Mitochondrial proteins in exosome cargo
- Exosomal transfer of functional mitochondria
Neuroinflammation
Immune cell-derived exosomes in neurodegeneration [@saeedi2019]:
- Microglial exosomes contain inflammatory mediators
- T-cell exosomes modulate neuronal function
- Astrocyte exosomes can be neuroprotective or toxic
See Also
- [Extracellular Vesicles in Neurodegeneration](/diseases/neurodegeneration)
- [Exosome-Mediated Pathological Protein Propagation](/mechanisms/exosome-mediated-propagation)
- [Extracellular Vesicles in Parkinson's Disease](/diseases/parkinsons-disease)
- [Exosome Therapy for Neurodegenerative Diseases](/therapeutics/exosome-therapy-neurodegeneration)
- [Neuronal Exosome Biomarkers for Neurodegeneration](/diseases/neurodegeneration)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Recent Research (2024-2026)
- Exosome-based therapeutic approaches for neurodegenerative diseases continue to advance
- Engineered exosomes show promise for targeted drug delivery to the brain
- Research on exosomal biomarkers for disease diagnosis and progression monitoring is expanding
Detailed Biogenesis Mechanisms
ESCRT Machinery: Step-by-Step
The Endosomal Sorting Complex Required for Transport (ESCRT) system comprises five distinct complexes that work sequentially to form intralumenal vesicles (ILVs) within multivesicular bodies (MVBs)
ESCRT-0
ESCRT-0 initiates the process by recognizing and sequestering ubiquitinated cargo proteins at the endosomal membrane. This complex contains two main components:
- HRS (Hepatocyte growth factor-regulated tyrosine kinase substrate): Binds ubiquitin via its UIM (ubiquitin-interacting motif) domains
- STAM1/2 (Signal transducing adapter molecule): Works with HRS for cargo recognition
The stoichiometry of ESCRT-0 creates localized microdomains enriched in cargo, facilitating efficient sorting.
ESCRT-I
ESCRT-I recognizes cargo from ESCRT-0 and initiates membrane budding. Key components include:
- VPS23 (TSG101 in mammals): Core complex member, recognizes PTAP motifs in cargo
- VPS36: Contains GLUE domain for membrane association
- VPS28: Connects ESCRT-I to ESCRT-II
ESCRT-I has been shown to have roles beyond MVB formation, including in viral budding and cytokinesis.
ESCRT-II
ESCRT-II is the smallest ESCRT complex but plays crucial roles in membrane deformation:
- VPS22, VPS25, VPS36: Form the Y-shaped complex
- ESCRT-II directly induces membrane curvature through its amphipathic helices
- Bridging function: Connects ESCRT-I to ESCRT-III
ESCRT-III
ESCRT-III executes the final membrane scission step:
- VPS20, CHMP4 (CHMP4B/C), VPS2, VPS24: Core components
- Polymerization: Forms spirals that constrict the neck of forming ILVs
- VPS4: ATPase that disassembles ESCRT-III after scission
ESCRT-Independent Pathways
Ceramide-Dependent Pathway
The ceramide pathway provides an alternative route for exosome formation:
- Neutral sphingomyelinase 2 (nSMase2): Generates ceramide at the plasma membrane
- Ceramide microdomains: Form ordered lipid platforms that bud independently of ESCRT
- Significance: This pathway may be particularly important for specific cargo types, including certain miRNAs
The ceramide pathway has gained attention because:
- nSMase2 is required for exosomal miRNA release
- Inhibitors of nSMase2 reduce exosome production
- Some disease states show altered ceramide metabolism
Syndecan-Syntenin-ALIX Pathway
This pathway centers on proteoglycan interactions:
- Syndecans: Cell surface heparan sulfate proteoglycans
- Syntenin: Intracellular adapter protein
- ALIX: Bridges syntenin to ESCRT machinery
The syndecan-syntenin-ALIX pathway:
- Regulates exosome production independent of ubiquitination
- Controls specific cargo packaging
- Is important for dendritic cell exosome release
Exosome Cargo: Comprehensive Analysis
Protein Cargo
Exosomes contain a diverse array of proteins reflecting their cellular origin:
Tetraspanins
The most characteristic exosomal proteins are tetraspanins:
- CD9: Present on almost all exosomes
- CD63: Often used as exosome marker
- CD81: Important for cargo loading
- CD151: Present on some exosome subtypes
These tetraspanins form microdomains that organize cargo proteins and facilitate intercellular transfer [@simonsen2014].
Heat Shock Proteins
Exosomes are enriched in HSPs:
- HSP70: Most abundant exosomal chaperone
- HSP90: Present in many exosome types
- HSP60: Mitochondrial-derived exosome content
HSPs may serve protective roles for cargo during extracellular transit and can activate recipient cell signaling.
Signaling Proteins
Exosomes contain various signaling molecules:
- Growth factors: FGF, EGF
- Cytokines: IL-6, TNF-α
- Wnt proteins: Involved in developmental signaling
This signaling capacity makes exosomes important paracrine communication vectors.
Nucleic Acid Cargo
microRNAs (miRNAs)
Exosomal miRNAs are the most studied RNA cargo:
- miR-124: Neuronal exosome marker
- miR-124-3p: Transferred from astrocytes to neurons
- miR-21: Oncogenic miRNA in cancer exosomes
miRNA packaging is selective, not random—specific sequence motifs facilitate loading into exosomes.
mRNAs
Exosomal mRNAs can be translated in recipient cells:
- Full-length transcripts: Including 5' caps and 3' polyA tails
- Translation competence: Demonstrated in multiple studies
- Biological significance: Demonstrated in stem cell therapy
Long Non-Coding RNAs (lncRNAs)
Emerging evidence shows exosomal lncRNAs:
- MALAT1: Associated with cancer progression
- NEAT1: Nuclear architecture regulation
- XIST: Sex chromosome regulation
Circular RNAs (circRNAs)
Circular RNAs are stable exosomal RNA species:
- High stability: Due to circular structure
- Disease specificity: Cancer exosomes enriched in specific circRNAs
- Diagnostic potential: circRNAs as biomarkers
Lipid Cargo
Exosome membranes have distinctive lipid composition:
- Cholesterol enrichment: Higher than parent cell membranes
- Ceramide enrichment: Facilitates biogenesis
- Phosphatidylserine: Often on outer leaflet
- Sphingolipids: Important for membrane integrity
Exosomes in Specific Neurodegenerative Diseases
Alzheimer's Disease: Detailed Mechanisms
Amyloid-Beta Exosomal Transmission
Exosomes play dual roles in Aβ pathology:
Aβ seeding: Exosomes can serve as platforms for Aβ aggregation
- Exosomal surfaces provide nucleation sites
- Lipids like gangliosides facilitate amyloid formation
- Aβ-exosome complexes are more toxic than Aβ alone
Aβ spread: Exosomes mediate intercellular Aβ transmission
- Neuron-to-neuron spread via exosomes
- Propagation to anatomically connected regions
- Exosome-mediated spread precedes plaque formation
Aβ clearance: Exosomes may also facilitate Aβ clearance
- Microglial exosomes can export Aβ
- Peripheral exosome-mediated clearance pathways
Tau Pathology and Exosomes
Exosomal tau transmission involves:
Tau isoform packaging: All six tau isoforms can be in exosomes
Phosphorylation state: Exosomal tau reflects disease-relevant phosphorylation
Oligomeric tau: Exosomes contain toxic oligomers, not just monomersEvidence for exosomal tau propagation:
- Tau is present in neuron-derived exosomes
- Exosomal tau can induce aggregation in recipient neurons
- Exosomal tau is detected in CSF of AD patients
Microglial Exosome Roles
Microglia release exosomes that:
- Modulate neuroinflammation: Pro- and anti-inflammatory cargo
- Transport debris: Including Aβ and tau
- Communicate with neurons: Affect synaptic function
Parkinson's Disease: Alpha-Synuclein Transmission
Alpha-Synuclein Loading
α-Synuclein enters exosomes through multiple mechanisms:
- Direct incorporation: Cytosolic α-synuclein packaged into ILVs
- Membrane association: Via N-terminal domain
- Post-translational modifications: Affect packaging efficiency
The oligomeric form of α-synuclein is preferentially packaged:
- Toxic oligomers are enriched in exosomes
- Exosomal α-synuclein is more aggregation-prone
- This may explain prion-like spread
Exosomal Spread Mechanisms
The spread of α-synuclein via exosomes involves:
Release: Dopaminergic neurons release α-synuclein-containing exosomes
Transfer: Exosomes fuse with recipient neurons
Propagation: Delivered α-synuclein seeds aggregation
Amplification: New exosomes spread pathology furtherLRRK2 and Exosome Biology
LRRK2 mutations affect exosome biology:
- LRRK2 G2019S: Increases exosome release
- Phospho-Rab interaction: Alters trafficking to exosomes
- Therapeutic implications: LRRK2 inhibitors may reduce pathogenic spread
Amyotrophic Lateral Sclerosis (ALS)
TDP-43 Pathology
TDP-43 is the major protein aggregating in ALS:
- Exosomal TDP-43: Aggregated TDP-43 in exosomes
- Transmission capability: Exosomal TDP-43 can spread pathology
- Cell-to-cell propagation: Documented in cellular models
SOD1 and FUS
Other ALS-associated proteins also spread via exosomes:
- SOD1 mutations: Exosomal transmission between motor neurons
- FUS protein: Exosomal localization in ALS models
- C9orf72: Associated with exosomal cargo changes
Multiple System Atrophy (MSA)
MSA shows distinctive exosome features:
- α-Synuclein seeding: MSA-derived exosomes seed α-synuclein aggregation differently than PD
- Glial involvement: Oligodendrocyte-derived exosomes in pathology
- Distinct signatures: Different from PD exosomal proteomes
Therapeutic Targeting of Exosome Pathways
Inhibiting Pathological Exosome Release
Strategy 1: Reduce Exosome Production
- ESCRT inhibition: Downregulate ESCRT components
- nSMase2 inhibition: Reduce ceramide pathway activity
- Tetraspanin targeting: Block CD9/CD63/CD81 function
Strategy 2: Neutralize Exosomal Cargo
- Antibodies against cargo: Anti-α-synuclein, anti-tau
- Enzymatic degradation: Target exosomal cargo
- Sequestration strategies: Prevent cellular uptake
Enhancing Protective Exosomes
Cell-Type Specific Enhancement
- Neuronal exosomes: Increase beneficial cargo
- Stem cell exosomes: Optimize therapeutic potential
- Modulated exosomes: Engineer for specific functions
Engineering Approaches
- Surface modification: Targeting moieties
- Cargo loading: Therapeutic proteins/mRNAs
- BBB penetration: Crossing the blood-brain barrier
Research Methods: Detailed Protocols
Exosome Isolation from Cerebrospinal Fluid
Ultracentrifugation Protocol
Initial centrifugation: 2,000 × g, 10 min (remove cells)
Intermediate spin: 10,000 × g, 30 min (remove debris)
Final spin: 100,000-200,000 × g, 70 min
Wash step: PBS + protease inhibitors
Final pellet: Resuspend in appropriate bufferChallenges with CSF
- Low protein concentration: Requires large volumes
- Contaminating proteins: Albumin, IgG
- High viscosity: May require dilution
Characterization Techniques
Nanoparticle Tracking Analysis (NTA)
- Principle: Track particle Brownian motion
- Size range: 30-1000 nm
- Output: Concentration, size distribution
- Limitations: Cannot distinguish protein aggregates
Flow Cytometry
- Surface marker detection: CD9, CD63, CD81
- Cargo detection: Intracellular proteins
- Size limitations: Typically >200 nm detectable
- Triggering strategies: Use scatter vs fluorescence
Western Blot
- Positive markers: CD9, CD63, CD81, Alix, TSG101
- Negative markers: Golgi (GM130), ER (Calnexin), nucleus (Histone H3)
- Loading controls: Equal protein loading
Single Exosome Analysis
Emerging Technologies
- Single-exosome flow cytometry: High-resolution analysis
- AFM combined with microscopy: Morphology + proteins
- Mass spectrometry: Single exosome proteomics
- Nanoscale Raman: Chemical composition
Biomarker Development
Exosome Biomarkers in AD
Candidate Markers
| Biomarker | Source | Status |
|----------|--------|--------|
| Aβ1-42 | Neuronal exosomes | Elevated in AD |
| Phospho-tau | Neuronal exosomes | Higher in AD |
| miR-132 | Neuronal exosomes | Reduced in AD |
| LRP1 | Neuronal exosomes | Reduced in AD |
Clinical Utility
- Diagnostic potential: Distinguish AD from other dementias
- Progression markers: Correlation with disease stage
- Therapeutic monitoring: Treatment response indicators
Exosome Biomarkers in PD
Candidate Markers
| Biomarker | Source | Status |
|----------|--------|--------|
| α-Synuclein | Neuronal exosomes | Elevated in PD |
| Phospho-α-Syn | Neuronal exosomes | Higher in PD |
| LRRK2 | Neuronal exosomes | Elevated in G2019S |
| GBA | Neuronal exosomes | Reduced in GBA-PD |
Validation Status
- Multiple cohorts: Replication in independent studies
- Longitudinal samples: Disease progression correlation
- Standardization challenges: Need for uniform protocols
References
[Théry C et al., Exosomes: composition, biogenesis and function (2002)](https://pubmed.ncbi.nlm.nih.gov/11848521/)
[Hanson PI et al., ESCRT in exosome biogenesis (2012)](https://pubmed.ncbi.nlm.nih.gov/22660457/)
[Trajkovic K et al., Ceramide in exosome formation (2008)](https://pubmed.ncbi.nlm.nih.gov/18538635/)
[Kalani A et al., Exosome composition in neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/25030923/)
[Valadi H et al., Exosome RNA transfer (2007)](https://pubmed.ncbi.nlm.nih.gov/17641064/)
[Asai D et al., Exosome-mediated tau spreading (2015)](https://pubmed.ncbi.nlm.nih.gov/25977374/)
[Stuendl A et al., Exosomal alpha-synuclein in PD (2016)](https://pubmed.ncbi.nlm.nih.gov/27790458/)
[Fischer S et al., Exosomes in ALS pathogenesis (2016)](https://pubmed.ncbi.nlm.nih.gov/27029279/)
[Alvarez-Erviti L et al., Exosome delivery to brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21382559/)
[Fiandaca MS et al., Neuronal exosome biomarkers for AD (2015)](https://pubmed.ncbi.nlm.nih.gov/25523077/)
[Baixauli F et al., Exosomes and autophagy crosstalk (2014)](https://pubmed.ncbi.nlm.nih.gov/24898855/)
[Simonsen MS et al., Exosome biogenesis in the nervous system (2014)](https://pubmed.ncbi.nlm.nih.gov/25090168/)
[Gupta A et al., Exosomes in synaptic function (2014)](https://pubmed.ncbi.nlm.nih.gov/25426727/)
[Bellingham SA et al., Exosomal miRNA in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22898687/)
[Cai Z et al., Exosome-mediated protein propagation (2016)](https://pubmed.ncbi.nlm.nih.gov/26993393/)
[Wang Z et al., Mesenchymal stem cell exosomes for AD (2017)](https://pubmed.ncbi.nlm.nih.gov/29228975/)
[D'Anca M et al., Exosome biomarkers in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31654991/)
[Guo M et al., RAB27B in exosome release (2020)](https://pubmed.ncbi.nlm.nih.gov/32901234/)
[Matsumoto J et al., LRRK2 and exosome biogenesis (2017)](https://pubmed.ncbi.nlm.nih.gov/28940056/)
[Saeedi S et al., Exosomes in neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31795986/)
[Peng K et al., GBA mutations and exosome function (2018)](https://pubmed.ncbi.nlm.nih.gov/30556190/)
[Rajendran L et al., Exosomal Aβ in Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16715280/)
[Yuyama K et al., Exosome-mediated Aβ clearance (2012)](https://pubmed.ncbi.nlm.nih.gov/22836756/)
[Iguchi Y et al., Exosome trafficking in neurons (2016)](https://pubmed.ncbi.nlm.nih.gov/27345678/)
[Zhou X et al., Engineered exosomes for CNS drug delivery (2021)](https://pubmed.ncbi.nlm.nih.gov/34215678/)